Annual General Meeting 2015 and information about members appointed to the Nomination Committee

The Annual General Meeting in NeuroVive Pharmaceutical AB (publ) will be held on
Wednesday 29 April, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund,
Sweden.
Shareholders are entitled to have a matter addressed by the Annual General
Meeting as long as their request has been received by the Board of Directors by
27 February 2015. The Board of Directors can be contacted by email at:
styrelsen@neurovive.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Greg
Batcheller, Medicon Village, 223 81 Lund, Sweden.

The AGM on 9 May 2014 resolved that NeuroVive shall have a Nomination Committee
comprising one member of each of the three largest shareholders in terms of
voting rights based on ownership statistics maintained by Euroclear Sweden AB as
of 30 June 2014. If a shareholder does not exercise its right to appoint a
member, entitlement to appoint a member of the Nomination Committee shall
transfer to that member who is the second largest shareholder in terms of voting
rights. The Nomination Committee’s period of office runs until a new Nomination
Committee has been appointed.

The Nomination Committee ahead of the AGM 2015 comprises:

  · Michael Vickers (Chairman of the Nomination Committee) appointed by Maas
Biolab LLC,
  · Anders Ermén appointed by Baulus Capital Belgium SA, and
  · Tomas Hagström appointed by Eskil Elmér.

In total, the Nomination Committee represents some 30% of the votes in NeuroVive
as of 30 September 2014.

The Nomination Committee’s task ahead of the AGM 2015 is to prepare proposals on
the following matters to present to the AGM for resolution:

  ·  Propose the Chairman of the AGM,
  ·  Propose the number of Board members and, where applicable, the number of
Auditors,
  ·  Propose remuneration to Board members and remuneration to Committee
members,
  ·  Propose remuneration to the Auditors,
  ·  Propose the Chairman of the Board and other Board members and, where
applicable, Auditors,
  ·  Propose guidelines for appointing members of the Nomination Committee and
the assignments of the Nomination Committee,
  ·  Propose remuneration to the members of the Nomination Committee.

Shareholders wishing to propose members of the Nomination Committee can contact
the Committee by email at: valberedningen@neurovive.com, or by mail at:
NeuroVive Pharmaceutical AB, FAO: Nomination Committee, Medicon Village, 223 81
Lund, Sweden. In order for the Nomination Committee to consider the proposals
received with due care, proposals must be received by the Nomination Committee
by no later than 16 February 2015.

About NeuroVive Pharmaceutical

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of antiviral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 29 October 2014, at 8.30 a.m. CET.